Guggenheim on Spyre Therapeutics (SYRE): 'remains one of our Top 2026 Picks'

March 16, 2026 10:39 AM

Guggenheim on Spyre Therapeutics (NASDAQ: SYRE): 'remains one of our Top 2026 Picks'.The analyst comments "This morning, Spyre announced the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found